BPTS BIOPHYTIS SA AMERICAN DEPOSITARY SHARE

Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia

Biophytis / Key word(s): Miscellaneous
Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia

15-May-2023 / 08:00 CET/CEST


Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia

 

 

Paris (France), Cambridge (Massachusetts, U.S.), May 15, 2023, 08:00 CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announced that it has submitted the application for Clinical Trial Authorization (CTA) to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA (European Medicines Agency).

 

The launch of the Phase 3 program follows encouraging results from the SARA-INT Phase 2b study and interactions with health authorities in 2022. Based on the Phase 2b results and feedback from the agencies, Biophytis is starting its Phase 3 programme by filing the first Phase 3 (SARA-31) application in Europe.

 

The objective of the SARA-31 phase 3 study in sarcopenia is to evaluate the efficacy and safety of Sarconeos (BIO101) in the treatment of sarcopenic patients at risk of mobility disability. Approximately 900 patients over 65 years of age with severe sarcopenia (3 ≤ SPPB ≤ 7) with low walking speed (4-m Gait speed  ≤ 0.8 m/s) and low grip strength (HGS < 20kg for women and < 35.5 kg for men) will be included. They will be treated for a minimum of 12 months and a maximum of 36 months, receiving either placebo or 350mg of Sarconeos (BIO101) twice daily. The primary endpoint will be the assessment of the risk of Major Mobility Disability (MMD), measured by the ability to walk 400m in less than 15 minutes over time. In addition to this primary endpoint, the following secondary endpoints will be assessed: walking speed (4-m walking speed from the Short Physical Performance Battery (SPPB) test), handgrip strength (HGS) and patient-reported quality of life (Patient Reported Outcome SarQol, a questionnaire developed specifically for sarcopenia).

 

Biophytis expects a response from the regulatory authorities in the next quarter, which would allow Biophytis to initiate the study in Belgium in the following quarter. In addition, Biophytis is currently working on the preparation of the documents to be submitted to the FDA in order to request approvals to initiate the phase 3 study also in the United States. Finally, the principal investigator of the study will be Roger A. Fielding, PhD, who heads the Nutrition, Physiology, Exercise and Sarcopenia (NEPS) laboratory at Tufts University in Boston, who will continue with his contribution to the clinical development plan of  Sarconeos(BIO101).

 

Stanislas Veillet, CEO of Biophytis stated: “Sarcopenia has only recently been recognised as a diagnosable disease, with no effective treatment option, despite the enormous medical need. Following the successful completion of the SARA-INT Phase 2b trial to assess the safety and efficacy of Sarconeos (BIO101) in patients over 65 years of age with sarcopenia and at risk of mobility disability, the submission of the EMA application to initiate a Phase 3 trial in sarcopenia marks the beginning of a new milestone in the development of our drug candidate. There is currently no drug approved in the world for sarcopenia. We are pioneers in this field and intend to continue to establish our leadership by being the first company to launch, in partnership with global or regional pharmaceutical companies, a Phase 3 clinical development program in this indication.”

 

About BIOPHYTIS

 

Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our lead molecule drug candidate, administered orally, has completed a Phase 2 clinical trial as a treatment for sarcopenia in the United States and Europe (SARA-INT) with promising results. Sarconeos has also obtained positive results from a Phase 2-3 clinical trial (COVA) for the treatment of severe forms of COVID-19 in Europe, Latin America and the United States. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).

The Company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040).

For more information visit

Disclaimer

 

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2022 Annual Report on Form 20-F available on BIOPHYTIS website () and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Biophytis Contact for Investor Relations

Philippe Rousseau CFO

 

Media Contacts

Antoine Denry:    27
Agathe Boggio:    42



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: Biophytis
14 avenue de l´Opéra
75001 Paris
France
Internet:
ISIN: US09076G1040, FR0012816825
EQS News ID: 1632425

 
End of Announcement - EQS News Service

1632425  15-May-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1632425&application_name=news&site_id=research_pool
EN
15/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOPHYTIS SA AMERICAN DEPOSITARY SHARE

 PRESS RELEASE

Biophytis publie ses comptes semestriels au 30 juin 2023 et fait le po...

Biophytis / Mot-clé(s) : Résultat semestriel Biophytis publie ses comptes semestriels au 30 juin 2023 et fait le point sur ses activités 27-Sep-2023 / 23:15 CET/CEST   Biophytis publie ses comptes semestriels au 30 juin 2023 et fait le point sur ses activités     Démarrage du développement industriel de Sarconeos (BIO101) dans la perspective d’un accès au marché dans les formes sévères de Covid-19 (COVA). Autorisations de démarrer l’étude de Phase 3 aux Etats-Unis et en Belgique dans la sarcopénie (SARA), une première mondiale, ouvrant la perspective de partenariats. Une s...

 PRESS RELEASE

Biophytis releases its half-yearly accounts as of 30 June 2023 and pro...

Biophytis / Key word(s): Half Year Results Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations 27-Sep-2023 / 23:15 CET/CEST   Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations     Start of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA) Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia (SARA), a world first, opening up the prospect of partnerships Cash position and secured fi...

 PRESS RELEASE

Biophytis and Skyepharma sign a Partnership Agreement for the Product...

Biophytis / Key word(s): Scheme of Arrangement Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) 25-Sep-2023 / 07:06 CET/CEST   Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)     Paris (France) and Cambridge (Massachusetts, USA), September 25,  2023 – 07:00 am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes as...

 PRESS RELEASE

Biophytis et Skyepharma signent un partenariat pour la production de ...

Biophytis / Mot-clé(s) : Arrangement Biophytis et Skyepharma signent un partenariat pour la production de Sarconeos (BIO101) 25-Sep-2023 / 07:06 CET/CEST   Biophytis et Skyepharma signent un partenariat pour la production de Sarconeos (BIO101)   Paris (France) et Cambridge (Massachusetts, États-Unis), 25 septembre 2023 – 07:00 – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), société de biotechnologie au stade clinique spécialisée dans le développement de traitements qui visent à ralentir les processus dégénératifs liés au vieillissement et à a...

 PRESS RELEASE

Biophytis fait le point sur ses programmes d’accès précoce pour Sarcon...

Biophytis / Mot-clé(s) : Autorisation d’agrément Biophytis fait le point sur ses programmes d’accès précoce pour Sarconeos (BIO101) dans le traitement des formes sévères de COVID-19 19-Sep-2023 / 07:00 CET/CEST   Biophytis fait le point sur ses programmes d’accès précoce pour Sarconeos (BIO101) dans le traitement des formes sévères de COVID-19     Paris (France) et Cambridge (Massachusetts, États-Unis), 19 septembre 2023 – 07:00 – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), société de biotechnologie au stade clinique spécialisée dans le dév...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch